Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global GLP-1 Receptor Agonist Global Market Report 2024

GLP-1 Receptor Agonist Global Market Report 2024 – By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs ), By Route Of Administration (Parenteral, Oral ), By End Users (Hospitals, Surgical Clinics, Other Users) – Market Size, Trends, And Global Forecast 2024-2033

GLP-1 Receptor Agonist Global Market Report 2024

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
Customise Your Report
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
GLP-1 Receptor Agonist Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Glp-1 Receptor Agonist Market Definition And Segments

A GLP-1 receptor agonist is a type of medication that stimulates insulin release at high blood glucose levels and suppresses glucagon secretion under low blood glucose conditions. They are used to treat type 2 diabetes mellitus.

The main drug class of GLP-1 receptor agonist is liraglutide, dulaglutide, lixisenatide, and others. Liraglutide is a GLP-1 receptor agonist that acts by helping the pancreas to release the right amount of insulin when blood sugar levels are high. The route of administration involved is parenteral, and oral which are used by hospitals, surgical clinics, and others.

The glp-1 receptor agonist market covered in this report is segmented –

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs

2) By Route Of Administration: Parenteral, Oral

3) By End Users: Hospitals, Surgical Clinics, Other Users

The glp-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.1 billion in 2023 to $13.74 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rising diabetes prevalence, clinical efficacy, patient awareness and acceptance, global health initiatives, patient preference for injectable therapies.

The glp-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $16.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches.

Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market

The rising prevalence of diabetes is expected to propel the GLP-1 receptor agonist market going forward. Diabetes is a chronic illness that develops when the pancreas either produces insufficient amounts of insulin or when the body cannot properly utilize the insulin that it does. High blood sugar is a symptom of the metabolic disorder diabetes mellitus. GLP-1 receptor agonist is used in diabetes to stimulate the body to produce more insulin, which helps to lower blood sugar levels, so the rising prevalence of diabetes will propel the market growth. For instance, in December 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of over 230 national diabetes associations, the global population living with diabetes is approximately 537 million adults and further it is projected to rise to 643 million by 2030. Therefore, the rising prevalence of diabetes is driving the GLP-1 receptor agonist market.

Rising Obesity Epidemic Fuels Surge In The Glp-1 Receptor Agonist Market

The increasing cases of obesity are expected to boost the growth of the GLP-1 receptor agonist market going forward. Obesity refers to a medical condition characterized by the excessive accumulation of body fat, often resulting in an individual having a body mass index (BMI) of 30 or higher and is associated with various health risks and complications. GLP-1 receptor agonists (GLP-1RAs) are a class of medications that have been shown to be effective in treating obesity by mimicking the effects of a naturally occurring hormone called GLP-1, which helps to regulate appetite and blood sugar levels. For instance, in March 2022, according to the World Health Organization, a Switzerland-based public health organization, over 1 billion individuals globally were affected by obesity, comprising 650 million adults, 340 million adolescents, and 39 million children, with this figure continuing to rise. Further, it is estimated that around 167 million people are expected to experience compromised health due to being overweight or obese. Therefore, the increasing cases of obesity are driving the growth of the GLP-1 receptor agonist market.

Major companies operating in the glp-1 receptor agonist market report are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., 9 Meters Biopharma Inc., Intarcia Therapeutics Inc., Amylin Pharmaceuticals Inc., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., CymaBay Therapeutics Inc., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., Genentech Inc., GlaxoSmithKline PLC, HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Kowa Company Ltd., LG Chem Ltd., Ligand Pharmaceuticals Incorporated, Merck & Co. Inc., Novartis AG .

Innovative Breakthroughs Transform The Glp-1 Receptor Agonist Market

Product innovations are a key trend gaining popularity in the GLP-1 receptor agonist market. Major companies operating in the GLP-1 receptor agonist market are focused on developing innovative solutions to strengthen their position. For instance, in May 2022, Eli Lilly and Company, a US-based pharmaceutical company that creates medicines that make life better for people, launched the FDA-approved new Mounjaro, a GIP and GLP-1 receptor agonist. It is specially designed using a single molecule that turns on the body's receptors for the incretin hormones GIP and GLP-1. It is available as a pen auto-injector with a pre-attached, hidden needle that patients do not need to handle or see, and it comes in 6 doses.

Sustained-Release Glp-1 Receptor Agonists Are Gaining Popularity

Major companies operating in the GLP-1 receptor agonist market are focused on developing sustained-release GLP-1 receptor agonists to gain a competitive edge in the market. Sustained-release GLP-1 receptor agonists (GLP-1RAs) are a type of medication that slowly releases GLP-1RA into the bloodstream over time, which allows for longer-lasting effects and less frequent injections compared to traditional GLP-1RAs. For instance, in April 2023, Mitsubishi Tanabe Pharma Corporation, a Japan-based pharmaceuticals company, launched Mounjaro 2.5 mg or 5 mg Ateos. It is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes that activates both the GLP-1 and GIP receptors. The GLP-1 receptor is involved in regulating blood sugar levels, while the GIP receptor is involved in stimulating insulin secretion and reducing appetite.

Sanofi Strengthens Biologics Portfolio With Acquisition Of Amunix Pharmaceuticals Inc.

In February 2022, Sanofi S.A., a France-based pharmaceutical and healthcare company that provides life-changing treatments, acquired Amunix Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, combined resources with Sanofi are expected to provide access to various products and technologies to Sanofi that can deliver next-generation conditionally activated biologics. Amunix Pharmaceuticals Inc. is a US-based immuno-oncology company that develops (GLP-1) receptor agonists and transformative therapies for cancer.

North America was the largest region in the GLP-1 receptor agonist market in 2023. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The GLP-1 receptor agonist market research report is one of a series of new reports from The Business Research Company that provides GLP-1 receptor agonist market statistics, including GLP-1 receptor agonist industry global market size, regional shares, competitors with GLP-1 receptor agonist market share, detailed GLP-1 receptor agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the GLP-1 receptor agonist industry. This GLP-1 receptor agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

GLP-1 Receptor Agonist Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $13.74 billion
Revenue Forecast In 2033 $16.82 billion
Growth Rate CAGR of 5.2% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Novo Nordisk A/S; Sanofi SA; Eli Lilly and Company; AstraZeneca Inc.; Boehringer Ingelheim International GmbH; Hanmi Pharm Co. Ltd.; Pfizer Inc.; Amgen Inc.; Innovent Biologics Inc.; Jiangsu Hengrui Medicine Co.; Sun Pharmaceuticals Industries Ltd.; 9 Meters Biopharma Inc.; Intarcia Therapeutics Inc.; Amylin Pharmaceuticals Inc.; PegBio Co. Ltd.; Zealand Pharma A/S; Bristol-Myers Squibb Company; Chongqing Lummy Pharmaceutical Co. Ltd.; CymaBay Therapeutics Inc.; Daiichi Sankyo Company Limited; Dong-A ST Co. Ltd.; Eisai Co. Ltd.; Genentech Inc.; GlaxoSmithKline plc; HanAll Biopharma Co. Ltd.; Ipsen SA; Johnson & Johnson; Kowa Company Ltd.; LG Chem Ltd.; Ligand Pharmaceuticals Incorporated; Merck & Co. Inc.; Novartis AG
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. GLP-1 Receptor Agonist Market Characteristics

    3. GLP-1 Receptor Agonist Market Trends And Strategies

    4. GLP-1 Receptor Agonist Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global GLP-1 Receptor Agonist Market Size and Growth

    5.1. Global GLP-1 Receptor Agonist Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global GLP-1 Receptor Agonist Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global GLP-1 Receptor Agonist Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. GLP-1 Receptor Agonist Market Segmentation

    6.1. Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Exenatide

    Liraglutide

    Dulaglutide

    Lixisenatide

    Other Drugs

    6.2. Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Parenteral

    Oral

    6.3. Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Surgical Clinics

    Other Users

    7. GLP-1 Receptor Agonist Market Regional And Country Analysis

    7.1. Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific GLP-1 Receptor Agonist Market  

    8.1. Asia-Pacific GLP-1 Receptor Agonist Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China GLP-1 Receptor Agonist Market  

    9.1. China GLP-1 Receptor Agonist Market Overview  

    9.2. China GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India GLP-1 Receptor Agonist Market  

    10.1. India GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan GLP-1 Receptor Agonist Market  

    11.1. Japan GLP-1 Receptor Agonist Market Overview  

    11.2. Japan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia GLP-1 Receptor Agonist Market  

    12.1. Australia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia GLP-1 Receptor Agonist Market  

    13.1. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea GLP-1 Receptor Agonist Market  

    14.1. South Korea GLP-1 Receptor Agonist Market Overview  

    14.2. South Korea GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe GLP-1 Receptor Agonist Market  

    15.1. Western Europe GLP-1 Receptor Agonist Market Overview

    15.2. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK GLP-1 Receptor Agonist Market  

    16.1. UK GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany GLP-1 Receptor Agonist Market  

    17.1. Germany GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France GLP-1 Receptor Agonist Market  

    18.5. France GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy GLP-1 Receptor Agonist Market  

    19.9. Italy GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain GLP-1 Receptor Agonist Market  

    20.13. Spain GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe GLP-1 Receptor Agonist Market  

    21.1. Eastern Europe GLP-1 Receptor Agonist Market Overview

    21.2. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia GLP-1 Receptor Agonist Market  

    22.1. Russia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America GLP-1 Receptor Agonist Market  

    23.1. North America GLP-1 Receptor Agonist Market Overview

    23.2. North America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA GLP-1 Receptor Agonist Market  

    24.1. USA GLP-1 Receptor Agonist Market Overview

    24.2. USA GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada GLP-1 Receptor Agonist Market  

    25.1. Canada GLP-1 Receptor Agonist Market Overview

    25.2. Canada GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America GLP-1 Receptor Agonist Market  

    26.1. South America GLP-1 Receptor Agonist Market Overview

    26.2. South America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil GLP-1 Receptor Agonist Market  

    27.1. Brazil GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East GLP-1 Receptor Agonist Market  

    28.1. Middle East GLP-1 Receptor Agonist Market Overview

    28.2. Middle East GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa GLP-1 Receptor Agonist Market  

    29.1. Africa GLP-1 Receptor Agonist Market Overview

    29.2. Africa GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. GLP-1 Receptor Agonist Market Competitive Landscape And Company Profiles

    30.1. GLP-1 Receptor Agonist Market Competitive Landscape

    30.2. GLP-1 Receptor Agonist Market Company Profiles

    30.2.1. Novo Nordisk A/S

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Sanofi SA

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Eli Lilly and Company

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. AstraZeneca Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Boehringer Ingelheim International GmbH

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global GLP-1 Receptor Agonist Market Competitive Benchmarking

    32. Global GLP-1 Receptor Agonist Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The GLP-1 Receptor Agonist Market

    34. GLP-1 Receptor Agonist Market Future Outlook and Potential Analysis

    34.1 GLP-1 Receptor Agonist Market In 2028 - Countries Offering Most New Opportunities

    34.2 GLP-1 Receptor Agonist Market In 2028 - Segments Offering Most New Opportunities

    34.3 GLP-1 Receptor Agonist Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Novo Nordisk A/S Financial Performance
  • Table 75: Sanofi SA Financial Performance
  • Table 76: Eli Lilly and Company Financial Performance
  • Table 77: AstraZeneca Inc. Financial Performance
  • Table 78: Boehringer Ingelheim International GmbH Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Novo Nordisk A/S Financial Performance
  • Figure 75: Sanofi SA Financial Performance
  • Figure 76: Eli Lilly and Company Financial Performance
  • Figure 77: AstraZeneca Inc. Financial Performance
  • Figure 78: Boehringer Ingelheim International GmbH Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Blood And Blood Components Global Market Report 2024 – By Product (Whole Blood, Blood Components), By Blood Components (Red Blood Cells, Platelets, Plasma, White Blood Cells), By End-User (Hospitals, Ambulatory Surgical Centers, Others), By Application (Anemia, Trauma and Surgery, Cancer Treatment, Bleeding Disorders) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Blood Group Typing Global Market Report 2024 – By Test Type (Antibody Screening, Cross-Matching Tests, ABO Tests, Antigen Typing, HLA Typing), By Product (Instruments, Reagents And Kits), By Techniques (Serology Tests, Molecular Tests), By End User (Hospital Based Laboratories, Independent Laboratories And Blood Banks) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Blood Glucose Meters Global Market Report 2024 – By Product type (Electrode Type Blood Glucose Meter, Photoelectric Blood Glucose Meter), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), By End User (Hospitals, Home Care) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Blood Cancer Drugs Global Market Report 2024 – By Blood Cancer Type (Leukemia, Lymphoma), By Drugs (Rituxan/Mabthera (Rituximab), Gleevec/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs), By Treatment Approaches (Key Findings, Chemotherapeutic, mAbs/Targeted Therapies, Immunotherapeutic) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Blood Transfusion Diagnostics Global Market Report 2024 – By Type (Instruments and Kits, Reagents, Other Types), By Technology (Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test), By Application (Blood Grouping, Disease Screening), By End User (Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Blood Collection Devices Global Market Report 2024 – By Type (Blood Collection Tubes, Lancet, Micro Container Tubes, Warming Devices), By Method (Manual Blood Collection, Automatic Blood Collection), By Material (Glass, Stainless Steel, Plastic), By End User (Hospitals, Blood Donation Centers, Diagnostic Center, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Dialysis Devices And Equipment Global Market Report 2024 – By Product (Hemodialysis Devices, Peritoneal Dialysis Devices, Continuous Renal Replacement Therapy (CRRT) Systems, Consumables), By Application (Serum And Blood Treatment, Virus Purification, Drug Binding Studies), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Hemodialysis And Peritoneal Dialysis Global Market Report 2024 – By Type (Hemodialysis, Short-Term Catheter, Chronic Catheter, Graft, Fistula, Peritoneal Dialysis), By Modality (Conventional, Daily (Day Time, Night Time)), By End User (Hospitals, Clinics, And Dialysis Centers, Home Dialysis) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the GLP-1 receptor agonist market?

A GLP-1 receptor agonist is a type of medication that stimulates insulin release at high blood glucose levels and suppresses glucagon secretion under low blood glucose conditions. They are used to treat type 2 diabetes mellitus. For further insights on the GLP-1 receptor agonist market, request a sample here

How will the GLP-1 receptor agonist market drivers and restraints affect the GLP-1 receptor agonist market dynamics? What forces will shape the GLP-1 receptor agonist industry going forward?

The GLP-1 receptor agonist market major growth driver - surging diabetes cases fuel growth in GLP-1 receptor agonist market. For further insights on the GLP-1 receptor agonist market, request a sample here

What is the forecast market size or the forecast market value of the GLP-1 receptor agonist market ?

The GLP-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.1 billion in 2023 to $13.74 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rising diabetes prevalence, clinical efficacy, patient awareness and acceptance,global health initiatives, patient preference for injectable therapies.. The GLP-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $16.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies.. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches.. For further insights on the GLP-1 receptor agonist market, request a sample here

How is the GLP-1 receptor agonist market segmented?

The GLP-1 receptor agonist market is segmented
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other UsersFor further insights on the GLP-1 receptor agonist market, request a sample here

Which region has the largest share of the GLP-1 receptor agonist market? What are the other regions covered in the report?

North America was the largest region in the GLP-1 receptor agonist market in 2023. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the GLP-1 receptor agonist market, request a sample here.

Who are the major players in the GLP-1 receptor agonist market?

Major companies operating in the GLP-1 receptor agonist market report are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., 9 Meters Biopharma Inc., Intarcia Therapeutics Inc., Amylin Pharmaceuticals Inc., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., CymaBay Therapeutics Inc., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., Genentech Inc., GlaxoSmithKline plc, HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Kowa Company Ltd., LG Chem Ltd., Ligand Pharmaceuticals Incorporated, Merck & Co. Inc., Novartis AG . For further insights on the GLP-1 receptor agonist market, request a sample here.

What are the key trends in the GLP-1 receptor agonist market?

Major trend in the GLP-1 receptor agonist market - innovative breakthroughs transform the GLP-1 receptor agonist market. For further insights on the GLP-1 receptor agonist market, request a sample here.

What are the major opportunities in the GLP-1 receptor agonist market? What are the strategies for the GLP-1 receptor agonist market?

For detailed insights on the major opportunities and strategies in the GLP-1 receptor agonist market, request a sample here.

How does the GLP-1 receptor agonist market relate to the overall economy and other similar markets?

For detailed insights on GLP-1 receptor agonist market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the GLP-1 receptor agonist industry?

For detailed insights on the mergers and acquisitions in the GLP-1 receptor agonist industry, request a sample here.

What are the key dynamics influencing the GLP-1 receptor agonist market growth? SWOT analysis of the GLP-1 receptor agonist market.

For detailed insights on the key dynamics influencing the GLP-1 receptor agonist market growth and SWOT analysis of the GLP-1 receptor agonist industry, request a sample here.